project id: TCGA-CESC; case submitter id: TCGA-FU-A40J; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.86; concentration: 0.16; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.86; rna integrity number: 7.1; age at index: 38; days to birth: -14182; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1974; age at diagnosis: 14182; ajcc pathologic m: MX; ajcc pathologic n: N1; ajcc pathologic t: T2a1; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 426.0; figo stage: Stage IIIB; icd 10 code: C53.9; last known disease status: not reported; morphology: 8384/3; primary diagnosis: Adenocarcinoma, endocervical type; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Cervix uteri; synchronous malignancy: No; tissue or organ of origin: Cervix uteri; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 76; days to sample procurement: 0; initial weight: 170.0; portion submitter id: TCGA-FU-A40J-01A-11; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 0.0; percent necrosis: 1.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 99.0; percent tumor nuclei: 75.0;